Moderators: ORCA , Stef07 , slops , whatarush12
Search This Board: 
Created: 10/27/2008 02:19:39 PM - Followers: 619 - Board type: Free - Posts Today: 6


VDRM

 


A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.

APPLICATIONS & USAGE
VITASTEM                                          





Available at ....  https://www.vitastem.net



ViaDerma Licensing FaceBook page at... https://www.facebook.com/ViaDermaInc

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________


https://www.vitastem.net/pages/before-afters









https://www.vitastem.net/products/vitastem

Vitastem treats Acne, Burns, Eczema, Infections, Psoriasis and Wounds

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year
     

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Contact Details

ViaDerma's global headquarters is located at

4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744

Email:  info@viadermalicensing.com


-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

 

VDRM CBD PATENT UPDATES


CBD Product launch!!!  

Initial order of 1,000 units sold into Canada have SOLD OUT!



https://elixrcannabis.com/

 

Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.

Per 12/7/17 PR:  The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. 

Per 1/23/18 PR:  The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.

The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.


What is CBD

CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and  Spray.

CBD in Skin Care

CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays,  and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
 

Dual Carrier Technology

Developed by a British Doctor and an American Pharmaceutical Company. Our Topical Products are formulated using Viaderma Pharmaceutical's Patent Pending Dual Carrier Technology. CBD is formulated into the carrier solution. This solution is then mixed with the professionally crafted skin care product using critically Essential Oils to maximize skin health care regime.

 

Elixr Hemp CBD Product Line

 

Our Elixr Hemp CBD Product line has a CBD Absorption Rate of 92% powered by Viaderma Pharmaceutical’s Patent Pending Dual Carrier Technology. Elixr Cannabis has the exclusive global rights to this groundbreaking technology combined with any Cannabinoids. Our products are second to none due to this independent laboratory tested high absorption rate combined with Elixr’s CDB profile.

Our CBD and Terpene profile, enriched with specific Essential Oils, Vitamin C, and Vitamin D, is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. CBD is known to have Anti-Inflammatory, Anti-Oxidant, and Anti-Aging properties that absorbs into the skin and provides overall healing benefits.

All our products are proudly Cruelty-free, 100% Toxin-free, Sodium Lauryl Sulfate free, Phthalate free, Parabens free, Petrochemicals free, Triclosan-free, Diethanolamine free and best of all, are handcrafted in Victoria, BC.


 



"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

 
INTELLECTUAL PROPERTY FILED BY DR. CHRIS AYO OTIKO
 PATENTS TRADEMARKS
NAME NUMBER NOTES NAME NUMBER STATUS
2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
VIADERMA'S ANNOUNCED DISTRIBUTORS
Business Name Owner Registered Otiko's Role
BIOGENX
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
TBD
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
TBD CA
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.
 



   ==============================================================================================

 

RECENT NEWS

https://www.globenewswire.com/search/keyword/ViaDerma%252520Licensing

https://www.otcmarkets.com/stock/VDRM/news
 



www.facebook.com/ViaDermaInc

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
#13415
EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/2017 03:10:04 PM
#61116
Must be tough to keep cheering for the Daboombooms 08/12/2022 09:24:47 PM
#61115
Hopefully not. Next week will be our week. Budman33 08/12/2022 06:04:24 PM
#61114
I THOUGHT I WAS GOING TO GET LUCKY ORCA 08/12/2022 05:40:11 PM
#61113
Post that the DR is out of the Grandmasim 08/12/2022 05:00:04 PM
#61112
That group of affiliated wound care practices, which YM4208 08/12/2022 02:06:11 PM
#61111
CEO is insane and disrespectful... Where are the Fdc4 08/12/2022 01:56:23 PM
#61109
Agree. That’s $135K better than ZERO Beninvest 08/11/2022 09:47:21 PM
#61108
I surmise the 2nd quarterly will be just gameccks1 08/11/2022 09:34:42 PM
#61106
Thanks for this. These people are insane Daboombooms 08/11/2022 08:50:09 PM
#61105
Thank you for your opinion. Here’s an old PR- Beninvest 08/11/2022 08:03:32 PM
#61104
Come on. Send in the clowns. What do sunrise73 08/11/2022 07:44:10 PM
#61103
Quarterly due next week I believe. I am Beninvest 08/10/2022 09:33:10 PM
#61102
WOW! Crickets. Out of excuses and nonsense it sunrise73 08/10/2022 07:23:40 PM
#61101
OTIKO =A TRUE LYING SCAMBAG.EVERYTIME. ORCA 08/10/2022 09:23:29 AM
#61100
Dr. OTIKO = STEPHEN BROWN FROM HPIL.... Same Fdc4 08/10/2022 02:03:14 AM
#61099
I CALLED IT.ARREST OTIKO. ORCA 08/08/2022 09:45:45 PM
#61098
Dr Otiko is a failure. History tells me Daboombooms 08/08/2022 09:26:51 PM
#61097
This CEO Dr. O, not sure what is Fdc4 08/08/2022 06:18:27 PM
#61096
What’s new….. I don’t expect a PR until Here Today 08/08/2022 01:58:22 PM
#61095
The DOC is out of the country won’t NeverShort 08/08/2022 01:57:29 PM
#61094
I sent an email over the weekend. Awaiting Beninvest 08/08/2022 12:53:44 PM
#61093
"NO BIG DEAL" ????? Huh??? Grandmasim 08/08/2022 12:37:18 PM
#61092
Perhaps us investors try to reach the Dr. retired early 08/08/2022 12:12:38 PM
#61091
So we wait till next week big F******* deal slops 08/08/2022 11:31:02 AM
#61090
SCAMBAG OTIKO WHERE IS THE UPDATE OF THE ORCA 08/08/2022 10:12:43 AM
#61089
Tons of great posts. Here is one from sunrise73 08/08/2022 06:03:21 AM
#61087
A lot of great posts! $VDRM share price, Hummingbird2 08/06/2022 08:21:26 PM
#61086
Why choose Vitastem Wound Care Treatment Vitastem is an FDA tw0122 08/06/2022 06:45:12 PM
#61085
Good stuff - thanks for sharing Beninvest 08/06/2022 06:38:26 PM
#61084
I have used it with great results, thanks Budman33 08/06/2022 06:00:01 PM
#61083
Check-out these Vitastem web sites: https://www.vitastem.net/pages/before-after indyterp 08/06/2022 05:57:40 PM
#61082
And the fabulous testing results should be announced. indyterp 08/06/2022 05:51:15 PM
#61080
Oh definitely! Daboombooms 08/06/2022 05:32:46 PM
#61079
I expect news this week, big orders, new Budman33 08/06/2022 04:09:16 PM
#61078
That’s a very conservative approach, based on the Fdc4 08/06/2022 03:55:22 PM
#61077
Should be .40+! indyterp 08/06/2022 10:19:13 AM
#61076
Within a 9 month window I believe we Budman33 08/06/2022 06:37:09 AM
#61072
Been a good week. Glad when so many Budman33 08/05/2022 05:26:16 PM
#61071
Another GREEN DAY it's all good $$ slops 08/05/2022 04:54:34 PM
#61070
Thanks for reposting some of my factual posts slops 08/05/2022 04:52:26 PM
#61069
Nope my posts are ALL FACT$ Thank You slops 08/05/2022 03:26:21 PM
#61067
This is not a stock for the weak slops 08/05/2022 03:20:03 PM
#61065
Just a matter of days PLENTY TO SELL slops 08/05/2022 03:16:51 PM
#61064
What a foolish thing to post JUST WATCH slops 08/05/2022 03:15:48 PM
#61063
Are you saying they will never have product again? Beninvest 08/05/2022 02:35:36 PM
#61062
What would a salesperson sell? Have you seen sunrise73 08/05/2022 01:55:54 PM
#61061
*ANY* revenue is a good thing** Beninvest 08/05/2022 01:22:18 PM
#61060
Agree. And revenue is good IMO. Plenty of Beninvest 08/05/2022 01:21:38 PM
#61059
The most logical outcome for the 2nd Qtr gameccks1 08/05/2022 12:51:15 PM
#61058
Quarterly due soon. Maybe they’ll pair that with Beninvest 08/05/2022 10:33:23 AM
Post Subject